Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases

Luminal A breast cancer is the most common breast cancer subtype which is usually treated with selective estrogen receptor modulators (SERMS) like tamoxifen. Nevertheless, one third of estrogen receptor positive breast cancer patients initially do not respond to endocrine therapy and about 40% of lu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Sommer, Ann-Katrin, Hermawan, Adam, Mickler, Frauke Martina, Ljepoja, Bojan, Knyazev, Pjotr, Bräuchle, Christoph, Ullrich, Axel, Wagner, Ernst, Roidl, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226596/
https://ncbi.nlm.nih.gov/pubmed/27409163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10459
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados